The differential effects of statins on the metastatic behaviour of prostate cancer

M. Brown; C. Hart; T. Tawadros; V. Ramani; V. Sangar; M. Lau; N. Clarke

doi:10.1038/bjc.2012.138

The differential effects of statins on the metastatic behaviour of prostate cancer

M. Brown, C. Hart, T. Tawadros, V. Ramani, V. Sangar, M. Lau, N. Clarke

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Article › peer-review

39 Downloads (Pure)

Abstract

Background: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown.Methods:Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins.Results:Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1μM) and rosuvastatin (5μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P

Original language	English
Pages (from-to)	1689-1696
Number of pages	7
Journal	British Journal of Cancer
Volume	106
Issue number	10
DOIs	https://doi.org/10.1038/bjc.2012.138
Publication status	Published - 8 May 2012

Keywords

Bone marrow stroma
Metastasis
Prostate cancer
Statins

Research Beacons, Institutes and Platforms

Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/bjc.2012.138

POST-PEER-REVIEW-PUBLISHERS.PDFFinal published version, 621 KB

Cite this

@article{afa97b286e9c4bccb6aefab2bb5847ed,

title = "The differential effects of statins on the metastatic behaviour of prostate cancer",

abstract = "Background: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown.Methods:Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins.Results:Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1μM) and rosuvastatin (5μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P",

keywords = "Bone marrow stroma, Metastasis, Prostate cancer, Statins",

author = "M. Brown and C. Hart and T. Tawadros and V. Ramani and V. Sangar and M. Lau and N. Clarke",

year = "2012",

month = may,

day = "8",

doi = "10.1038/bjc.2012.138",

language = "English",

volume = "106",

pages = "1689--1696",

journal = "BJC",

issn = "0007-0920",

publisher = "Springer Nature",

number = "10",

}

TY - JOUR

T1 - The differential effects of statins on the metastatic behaviour of prostate cancer

AU - Brown, M.

AU - Hart, C.

AU - Tawadros, T.

AU - Ramani, V.

AU - Sangar, V.

AU - Lau, M.

AU - Clarke, N.

PY - 2012/5/8

Y1 - 2012/5/8

N2 - Background: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown.Methods:Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins.Results:Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1μM) and rosuvastatin (5μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P

AB - Background: Although statins do not affect the incidence of prostate cancer (CaP), usage reduces the risk of clinical progression and mortality. Although statins are known to downregulate the mevalonate pathway, the mechanism by which statins reduce CaP progression is unknown.Methods:Bone marrow stroma (BMS) was isolated with ethical approval from consenting patients undergoing surgery for non-malignant disease. PC-3 binding, invasion and colony formation within BMS was assessed by standardised in vitro co-culture assays in the presence of different statins.Results:Statins act directly on PC-3 cells with atorvastatin, mevastatin, simvastatin (1μM) and rosuvastatin (5μM), but not pravastatin, significantly reducing invasion towards BMS by an average of 66.68% (range 53.93-77.04%; P

KW - Bone marrow stroma

KW - Metastasis

KW - Prostate cancer

KW - Statins

U2 - 10.1038/bjc.2012.138

DO - 10.1038/bjc.2012.138

M3 - Article

VL - 106

SP - 1689

EP - 1696

JO - BJC

JF - BJC

SN - 0007-0920

IS - 10

ER -

The differential effects of statins on the metastatic behaviour of prostate cancer

Abstract

Keywords

Research Beacons, Institutes and Platforms

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this